PCSK9 and atherosclerosis: A single intravenous injection of the PCSK9 mAb, alirocumab, in hyperlipidemic APOE*3Leiden.CETP transgenic mice, decreased non-HDL-C, inflammatory parameters, and atherosclerosis lesion size and improved plaque stability in a dose-dependent manner [152].